Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: A five-country observational study

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1237-1242

  Aravind, S R ^a   Tayeb, Khaled Al ^b   Ismail, Shaiful Bahari ^c   Shehadeh, Naim ^d   Kaddaha, Ghaida ^e   Liu, Rose ^f   Balshaw, Robert ^f   Lesnikova, Nadia ^f   Heisel, Olaf ^f   Girman, Cynthia J ^g   Musser, Bret J ^g   Davies, Michael J ^g   Katzeff, Harvey L ^g   Engel, Samuel S ^g   Radican, Larry ^g  

^a Diacon Hospital   (India)

^b AL NOOR SPECIALIST HOSPITAL   (Saudi Arabia)

^c HOSPITAL UNIVERSITI SAINS MALAYSIA   (Malaysia)

^d MEYER CHILDREN S HOSPITAL   (Israel)

^e RASHID HOSPITAL   (United Arab Emirates)

^f Syreon Corporation   (Canada)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Diabetes; Fasting; Hypoglycaemia; Ramadan

Indexed keywords

GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; SULFONYLUREA;

ADULT; ARTICLE; COMA; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INDIA; ISRAEL; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MORBIDITY; MOSLEM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; SAUDI ARABIA; SEIZURE; UNCONSCIOUSNESS; UNITED ARAB EMIRATES;

ADULT; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ISLAM; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 79956101975     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.578245     Document Type: Article

References (29)

1. Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med 2010;103:139-47
2. Al Arouj M, Assaad-Khalil S, Buse J et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care 2010;33:1895-902
3. Salti I, Benard E, Detournay B et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306-11 (Pubitemid 39281377)
4. Hui E, Bravis V, Hassanein M et al. Management of people with diabetes wanting to fast during Ramadan. BMJ 2010;340:c3053
5. Barnett AH, Cradock S, Fisher M et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract 2010;64:1121-9
6. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57: 3169-76
7. Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010: 340:b4909
8. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008;25:245-54 (Pubitemid 351322690)
9. JonssonL, BolinderB, LundkvistJ. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193-8
10. Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202 (Pubitemid 41638842)
11. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72 (Pubitemid 34256388)
12. Bell DS. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004;26:1714-27 (Pubitemid 40089487)
13. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55:S20-S27
14. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41 (Pubitemid 27341824)
15. Bodmer M, Meier C, Krahenbuhl S et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008;31:2086-91
16. Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002;58:45-53 (Pubitemid 34823624)
17. Cesur M, Corapcioglu D, Gursoy A et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007;75:141-7 (Pubitemid 44894596)
18. Devendra D, Gohel B, Bravis V et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009;63: 1446-50
19. The Glimepiride in Ramadan (GLIRA) Study Group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005;28:421-2
20. Belkhadir J, El Ghomari H, Klocker N et al. Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. BMJ 1993;307:292-5 (Pubitemid 23220845)
21. Sari R, Balci MK, Akbas SH, et al. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004;30:169-77 (Pubitemid 39243119)
22. Uysal AR, Erdogan MF, Sahin G et al. Clinical and metabolic effects of fasting in 41 type 2 diabetic patients during Ramadan. Diabetes Care 1998: 21:2033-4 (Pubitemid 28478319)
23. Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42 (Pubitemid 39120222)
24. Gonzalez-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications 2009;23:376-9
25. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996;28:426-9 (Pubitemid 26343732)
26. Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-84 (Pubitemid 28162078)
27. Tessier D, Dawson K, Tetrault JP et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994;11:974-80 (Pubitemid 24375836)
28. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDMpatients treated with oral hypoglycemic agents. Diabetes Care 1989;12:203-8 (Pubitemid 19071489)
29. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948-61 (Pubitemid 43942931)